Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06975410 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT06975410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Yuhan Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2025
Completion date
December 31, 2029
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

egfr overexpression, locally advanced solid tumor, metastatic solid tumor